Gourt > Health > Pharmacy > Drugs and Medications > R > Rituximab
.png | CAS_number = 174722-31-7 | ATC_prefix = L01 | ATC_suffix = XC02 | ATC_supplemental = | PubChem = | DrugBank = BTD00014 | chemical_formula = C6416H9874N1688O1987S44 | molecular_weight = 143859.7 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | pregnancy_category = | legal_status = | routes_of_administration = }} Rituximab, sold under the trade names Rituxan® and MabThera®, is a monoclonal antibody used in the treatment of B cell non-Hodgkin's lymphoma, B cell leukemia, and some autoimmune disorders.
History
Rituximab initially was approved by the FDA in 1997 for lymphoma that was refractory to other chemotherapy regimens. The original approval followed the availability of the McLaughlin et alMcLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33. PMID 9704735. study data. It now is standard therapy in the initial treatment of aggressive lymphomas (e.g. diffuse large B cell lymphoma) in combination with CHOP chemotherapy.
Mechanism
The antibody binds to the cluster of differentiation 20 (CD20) found on the surface of B cells, flagging them for destruction by the body's own immune system. This eliminates B cells (including the cancerous ones) from the body, allowing a new population of healthy B cells to develop from lymphoid stem cells. The actual mechanisms for Rituximab to eliminate B cells includes the induction of ADCC, CDC, and apoptosis. More on [ Rituximab ]
rituximab 4 prevention of chronic gvhd http://bit.ly/5GF1PV
localtrials (US Clinical Trials ) Sun, 20 Dec 2009 23:14:42 -0000
rituximab 4 prevention of chronic gvhd http://bit.ly/5GF1PV
rituximab 4 prevention of chronic gvhd http://bit.ly/5GF1PV
usclinicaltrial (US Clinical Trials) Sun, 20 Dec 2009 22:42:48 -0000
rituximab 4 prevention of chronic gvhd http://bit.ly/5GF1PV
rituximab 4 prevention of chronic gvhd http://bit.ly/5GF1PV
recruitingtrial (Recruiting Trials) Sun, 20 Dec 2009 21:50:39 -0000
rituximab 4 prevention of chronic gvhd http://bit.ly/5GF1PV
rituximab-hcvad in ppl w/ b-cell non-hodgkin's lymphoma http://bit.ly/6GIU7q
_clinical_trial (Clinical Trials) Sun, 20 Dec 2009 19:58:38 -0000
rituximab-hcvad in ppl w/ b-cell non-hodgkin's lymphoma http://bit.ly/6GIU7q
phase ii alemtuzumab & dose-adjusted epoch-rituximab in relapsed or refractory diffuse large b-cell & hodgkin lymphomas http://bit.ly/4yoD5w
usclinicaltrial (US Clinical Trials) Sun, 20 Dec 2009 19:46:44 -0000
phase ii alemtuzumab & dose-adjusted epoch-rituximab in relapsed or refractory diffuse large b-cell & hodgkin lymphomas http://bit.ly/4yoD5w
rituximab-hcvad in ppl w/ b-cell non-hodgkin's lymphoma http://bit.ly/6GIU7q
ustrials (US Trials) Sun, 20 Dec 2009 19:46:42 -0000
rituximab-hcvad in ppl w/ b-cell non-hodgkin's lymphoma http://bit.ly/6GIU7q
Rituxan - Genentech - Information about Non-Hodgkin's Lymphoma and Rituxan (Rituximab), the first U.S. approved monoclonal antibody cancer treatment to treat Non-Hodgkin's Lymphoma.
Meta Description: [ Rituxan (Rituximab) is the first monoclonal antibody cancer therapy approved in the United States. Healthcare professionals can find clinical trial, dosage and administration, and patient reimbursement information (SPOC). Presented by Genentech, Inc, and Idec Pharmaceuticals, Inc. ]
| Serious Infection in Lupus Patients Treated with Rituxan | |
| Next Video | |
